– USA, CA – Gemini BioProducts Holding, Inc., a portfolio company of BelHealth Investment Partners, LLC, today announced the appointment of Gopi Natarajan to its Board of Directors, bringing an incredible amount of operational experience to Gemini and will complement the skillset and experience of the current Board Members.
Brian Parker, CEO, said, “Gopi is a respected and proven leader, and we are excited to have him join the Board. With his expertise in managing rapid growth, he is uniquely qualified to bring fresh perspectives to our diverse Board. We are confident that Gopi’s valuable insights will help the Board and management team execute its strategic and business priorities.”
About Gopi Natarajan
Mr. Natarajan has more than thirty-five years of leadership experience in the healthcare industry. Most recently, he was the co-founder of Omega Healthcare and served as CEO for 18 years. Mr. Natarajan was instrumental in growing Omega from a startup into one of the largest revenue cycle management and clinical services companies, with over 30,000 employees and international delivery centers. He successfully led Omega through three successful exits before retiring in 2021.
Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life-enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company’s products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal-origin-free and animal-component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820.
For more information: https://www.geminibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.